As of today (2024-04-16), Ionis Pharmaceuticals's share price is $41.56. Ionis Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $2.68. Hence, Ionis Pharmaceuticals's Price to Tangible Book Ratio of today is 15.51.
The historical rank and industry rank for Ionis Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:
IONS'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.79 Med: 14.99 Max: 73.47
Current: 15.51
During the past 13 years, Ionis Pharmaceuticals's highest Price to Tangible Book Ratio was 73.47. The lowest was 5.79. And the median was 14.99.
IONS's Price-to-Tangible-Book is ranked worse than 93.94% of 1222
companies
in the Biotechnology industry
Industry Median: 2.81
vs IONS: 15.51
A closely related ratio is called PB Ratio. As of today, Ionis Pharmaceuticals's share price is $41.56. Ionis Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $2.68. Hence, Ionis Pharmaceuticals's P/B Ratio of today is 15.51.
Ionis Pharmaceuticals Price-to-Tangible-Book Historical Data
The historical data trend for Ionis Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Ionis Pharmaceuticals Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Price-to-Tangible-Book
5.87
11.09
5.79
9.37
18.88
Ionis Pharmaceuticals Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Price-to-Tangible-Book
9.37
10.51
13.71
20.62
18.88
Competitive Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Price-to-Tangible-Book Distribution
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Ionis Pharmaceuticals Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IONS has been successfully added to your 